Methicillin Resistant Staphylococcus Aureus Drugs Market Snapshot
|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The methicillin-resistant Staphylococcus Aureus Drugs market is expected to register a growth at a CAGR of 3.6% during the forecast period.
The major factors attributing to the growth of the Methicillin-Resistant Staphylococcus Aureus (MRSA) drugs market are a rise in the global prevalence of MRSA infections, a rise in private and public funding for R&D of novel anti-MRSA drug molecules and their improved screening.
For instance, According to the CDC, 2% of the general population carries MRSA. Additionally, the increased practice of prescribing unnecessary and inappropriate antibiotics resulting in the rise of MRSA infections is likely to drive the growth of the global MRSA drug market.
Scope of the Report
As per the scope of the report, staphylococcus aureus is an important pathogen known to be associated with various forms of infections in humans, pets, and poultry. But over the decades, MRSA have become resistant to beta-lactam antibiotic called methicillin. In chickens, this pathogen is associated with several disease manifestations such as comb necrosis, lameness, and septicemia. Also, MRSA usually spreads in the community by contact with infected people or things that are carrying the bacteria, which fuels high demand to form effective treatment, and driving the market.
|By Drug Class|
|By Route of administration|
|By Distribution Channel|
Key Market Trends
Lipopeptide Segment is Expected to Hold the Largest Market Share in the Market
Lipopeptide segment accounts for the major market share owing to the novel antibiotic therapy introduced for MRSA. The therapy includes daptomycin, a lipopeptide class of drug and linezolid, an oxazolidinone class of antibiotics. The rapid implementation of therapy is expected to fuel the market growth. Furthermore, the glycopeptides and lipoglycopeptides segment is expected to show significant growth, owing to the increasing focus of manufacturers on the development of advanced drugs in this class.
Parenteral route of administration accounted for highest market share due to increased investment by pharmaceutical manufacturers to boost the production of intravenous anti-MRSA antibiotics.
To understand key trends, Download Sample Report
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall MRSA drug market, throughout the forecast period. This dominance is mainly due to the investments by U.S. based companies in the R&D of screening tools for MRSA infection. Also, the rise in government support to treat MRSA lung infection in individuals with cystic fibrosis has fueled the market. For instance, in 2018, Cystic Fibrosis Foundation, at North American Cystic Fibrosis Conference announced that it will spend at least USD 100 million over the next five years to support improved detection, diagnosis, prevention, and treatment of infections related to cystic fibrosis.
Europe is the second most prominent region in the global MRSA drugs market, which is due to research grants by the public & private players in the European countries to propel the R&D of anti-MRSA antibiotics.
The Asia Pacific is set to grow at the fastest rate during the forecast period, driven by the huge patient pool in China and India, and the uncontrolled consumption of antibiotics in India is estimated to fuel the growth of the MRSA drugs market in the Asia Pacific.
To understand geography trends, Download Sample Report
The MRSA drug market is moderately competitive and consists of several prominent industry players. Some prominent players are acquiring blockbuster products in the market and expanding their market position. For instance, in 2018, Cumberland Pharmaceuticals Inc. acquired VIBATIV injection, an effective lipoglycopeptide class of drugs to treat MRSA, from Theravance Biopharma US, Inc. Whereas, other companies are making partnerships to consolidate their market leadership across the globe and while others are having new products in their pipeline. Some of the companies which are currently dominating the market are Melinta Therapeutics Inc., AbbVie Inc., Pfizer, Inc. Cumberland Pharmaceuticals Inc. and Merck & Co. Inc.
- In July 2021, Melinta Therapeutics announced the commercial launch of KIMYRSA, a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections. The U.S. Food and Drug Administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus
- In January 2020, Wockhardt announced regulatory approval to two novel antibiotics EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteremia. The new drug will target superbug like Methicillin-resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance
Table of Contents
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Prevalence of Global Infections and Demand for Novel Therapies
4.2.2 Rise in Research Activities to Develop Novel MRSA Drugs by Key Players and Support by Government Initiatives
4.3 Market Restraints
4.3.1 Lack of Systematic Surveillance for MRSA Infection in Developing Countries
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Drug Class
5.1.5 Folate Antagonist
5.2 By Route of administration
5.2.1 Oral Administration
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.4.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Cumberland Pharmaceuticals Inc
6.1.2 Pfizer Inc
6.1.3 AbbVie Inc.
6.1.4 Melinta Therapeutics Inc
6.1.5 Merck & Co Inc
6.1.6 Theravance Biopharma
6.1.7 Basilea Pharmaceutica
6.1.8 AmpliPhi Biosciences Corporation
6.1.9 Teva Pharmaceutical Industries ltd
6.1.10 Debiopharm International S.A.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Methicillin Resistant Staphylococcus Aureus Drugs Market market is studied from 2018 - 2026.
What is the growth rate of Methicillin Resistant Staphylococcus Aureus Drugs Market?
The Methicillin Resistant Staphylococcus Aureus Drugs Market is growing at a CAGR of >3.6% over the next 5 years.
Which region has highest growth rate in Methicillin Resistant Staphylococcus Aureus Drugs Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Methicillin Resistant Staphylococcus Aureus Drugs Market?
North America holds highest share in 2020.
Who are the key players in Methicillin Resistant Staphylococcus Aureus Drugs Market?
Pfizer Inc, Cumberland Pharmaceuticals Inc, Melinta Therapeutics Inc, Merck & Co Inc, AbbVie Inc. are the major companies operating in Methicillin Resistant Staphylococcus Aureus Drugs Market.